Conn.-based CooperSurgical to acquire a California fertility company
TRUMBULL — CooperSurgical is acquiring a California company that specializes in women’s fertility services for $1.6 billion, company officials have announced.
The company’s acquisition of privately held Generate Life Sciences is expected to close during the first quarter of 2022. CooperSurgical provides products and services for women’s health and fertility issues.
Holly Sheffield, president of CooperSurgical, said the acquisition of Generate Life Sciences will enhance “our comprehensive fertility solutions portfolio and furthers our ability to empower unique journeys to starting a family.”
In addition Embryo Options and Generate Life Sciences, CooperSurgical, which provides products and services for women’s health and fertility issues, has made three other acquisitions this year.
At the beginning of the year, CooperSurgical acquired a suburban Chicago-based company, Embryo Options, which works with fertility clinics to help patients with decisions related to frozen embryos, eggs and sperm. Generate Life Sciences is a provider of donor egg and sperm for fertility treatments, fertility cryopreservation services as well newborn stem cell storage of both umbilical cord blood and tissue.
In February, CooperSurgical acquired another California company, AEGEA Medical. AEGEA Medical developed a device to treat women with heavy menstrual bleeding during brief visits to a doctors office.
Two months after the AEGEA Medical acquisition, CooperSurgical acquired a British company, Safe Obstetric Systems, in a $52 million deal. Safe Obstetric Systems makes a device used to cradle the head of a baby being delivered by Caesarean section.
In May, CooperSurgical acquired obp Medical, a Massachusetts manufacturer of single-use illuminating medical devices.